Transient perforating folliculitis induced by sorafenib.
Minami-Hori
Masako
M
Ishida-Yamamoto
Akemi
A
Komatsu
Shigetsuna
S
Iiduka
Hajime
H
D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001557:Benzenesulfonates / Q000009:adverse effects* / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D005499:Folliculitis / Q000139:chemically induced* / Q000473:pathology; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008297:Male; D020556:Neutrophil Infiltration / Q000187:drug effects; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D011725:Pyridines / Q000009:adverse effects* / Q000627:therapeutic use; D012075:Remission, Spontaneous; D000077157:Sorafenib
D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib